21![](https://www.pdfsearch.io/img/553717fd0b0acc36ff3f5b86b929f927.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:19
|
---|
22![Shionogi & Co., Ltd. Impact of the 2011 off the Pacific coast of Tohoku Earthquake Osaka, Japan, March 15, Shionogi would like to express condolences to the victims and sincerely hope for the recovery of the peop Shionogi & Co., Ltd. Impact of the 2011 off the Pacific coast of Tohoku Earthquake Osaka, Japan, March 15, Shionogi would like to express condolences to the victims and sincerely hope for the recovery of the peop](https://www.pdfsearch.io/img/6cbe25c0230abcf07812f0433b2d34d4.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
23![](https://www.pdfsearch.io/img/658f302bcd8df2565077a25119e2fde9.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
24![Shionogi Announces the Conducting of International Industry-Academic Collaboration, SHIONOGI Science Program, and Drug Discovery Competition, FINDS2011 Osaka, October 3, 2011 – Shionogi & Co., Ltd. (Head Office: Osaka; Shionogi Announces the Conducting of International Industry-Academic Collaboration, SHIONOGI Science Program, and Drug Discovery Competition, FINDS2011 Osaka, October 3, 2011 – Shionogi & Co., Ltd. (Head Office: Osaka;](https://www.pdfsearch.io/img/4f4cc76a4bca64cd059f5d1fc7c2b023.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
25![Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines Osaka, Japan, March 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tes Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines Osaka, Japan, March 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tes](https://www.pdfsearch.io/img/a38387b5cdfb2c9dfccf11f684795b0c.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English |
---|
26![Shionogi participates in the Global Health Innovative Technology Fund Osaka, Japan, April 8, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announ Shionogi participates in the Global Health Innovative Technology Fund Osaka, Japan, April 8, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announ](https://www.pdfsearch.io/img/deb1aa902f5b1ff4ef3ff3200e59b548.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
27![Shionogi and Shire to Collaborate on the Development and Commercialization of the Therapeutic Agents for Attention-Deficit/Hyperactivity Disorder Osaka, Japan, November 18, Shionogi & Co., Ltd. (Head Office: Osaka Shionogi and Shire to Collaborate on the Development and Commercialization of the Therapeutic Agents for Attention-Deficit/Hyperactivity Disorder Osaka, Japan, November 18, Shionogi & Co., Ltd. (Head Office: Osaka](https://www.pdfsearch.io/img/95489027a1704efb4450b0ab2cb2b105.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:17
|
---|
28![Financial Results for the Third Quarter of Fiscal Year 2012(Consolidated) February 4, 2013 Name of Listed Company: SHIONOGI & CO., LTD. Financial Results for the Third Quarter of Fiscal Year 2012(Consolidated) February 4, 2013 Name of Listed Company: SHIONOGI & CO., LTD.](https://www.pdfsearch.io/img/5821ae633ab4b07762b0376362a57f88.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
29![NOT FOR IMMEDIATE RELEASE SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION FLORHAM PARK, NJ (March 30, 2015) – Naldemedine, an i NOT FOR IMMEDIATE RELEASE SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION FLORHAM PARK, NJ (March 30, 2015) – Naldemedine, an i](https://www.pdfsearch.io/img/93bb0edfe66ac4bbe402b8679bf7906f.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2015-04-27 07:57:32
|
---|
30![Shionogi Enters into Settlement Agreement with Generic Manufacturers over Crestor® Patent Osaka, Japan, March 26, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter Shionogi Enters into Settlement Agreement with Generic Manufacturers over Crestor® Patent Osaka, Japan, March 26, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter](https://www.pdfsearch.io/img/4465a0426c031665987c3358b3730c78.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|